标题加摘要与仅标题的第一级查方法:使用饮食模式和肉症风险的系统审查来比较查绩效的案例研究
Lynn Teo1, Mary E Van Elswyk2, Clara S Lau3
1Teo Research Consulting, Portland, ME, USA.
Systematic reviews
|November 14, 2023
概括
标题加摘要选在系统审查中比仅标题选更有效,提高了准确性并降低了缺失证据的风险. 这提高了系统审查结果的可靠性.
科学领域:
- 医学研究 医学研究
- 证据综合 证据综合
- 系统审查方法论 系统审查方法论
背景情况:
- 系统审查对于基于证据的实践至关重要,但需要大量的时间和资源.
- 在系统性审查的选阶段优化效率是研究人员感兴趣的关键领域.
- 在查过程中确保准确性和严格性对于系统审查结果的有效性至关重要.
研究的目的:
- 在系统性审查的第一级,比较仅标题 (Ti/O) 与标题加摘要 (Ti+Ab) 方法的选性能.
- 评估Ti/O和Ti+Ab选方法在研究识别中的定性和定量差异.
- 评估不同查策略对证据检索的准确性和完整性的影响.
主要方法:
- 采用了一个案例研究设计,同时比较Ti/O和Ti+Ab选方法.
- 对查的表现进行了评估,对照了对饮食模式和肉类症风险的系统综述的最终纳入研究.
- 统计分析,包括应急表,用于确定灵敏度,特异性,准确性和预测能力.
主要成果:
- Ti+Ab方法正确识别了36个引用,只有2个错误排除,而Ti/O错误排除了16个引用.
- 与Ti/O (Chi-squared: 2.92, p=0.0874) 相比,Ti+Ab方法的性能显著更高 (奇平方: 5.21,p=0.0225).
- 对Ti+Ab (94.7%) 和Ti/O (57.9%) 的敏感性明显更高,这表明相关研究的识别更好.
结论:
- 标题加摘要 (Ti+Ab) 选方法在捕获系统审查相关研究方面优于仅标题 (Ti/O).
- 使用Ti+Ab选可以增加准确可选引用的包含,并减少错过关键证据的风险.
- Ti/O方法可能会导致证据选择偏差,因为排除相关研究的可能性更高.
相关概念视频
Study Designs in Epidemiology
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and case-control studies.
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...


